Qulipta Tablet
Product Images NDC 0074-7094

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Qulipta (NDC 0074-7094). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Abbvie Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

The Active Ingredient Of Tradename Is Atogepant, A Calcitonin Gene-related Peptide (cgrp) Receptor Antagonist. The Chemical Name Of Atogepant Is (s)-n-((3s,5s,6r)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)piperidin-3-yl)-2'-oxo-1',2',5,7-tetrahydrospiro[cyclopenta[b]pyridine-6,3'-pyrrolo[2,3-b]pyridine]-3-carboxamide And Has The Following Structural Formula: (Qulipta 01)

Chemical structure diagram of Atogepant, the active ingredient in Qulipta tablets. The diagram depicts the molecular framework with atoms and bonds, illustrating the chemical composition of this oral prescription medication.*

FDA Label Image

Figure 1 (Qulipta 02)

Line graph showing the change from baseline in monthly migraine days over 12 weeks for placebo and Atogepant tablets at 10 mg, 30 mg, and 60 mg dosages. The graph includes error bars representing standard error and indicates a greater reduction in migraine days for Atogepant compared to placebo over the treatment period.*

FDA Label Image

Figure 2 (Qulipta 03)

Bar chart comparing the percentage of patients experiencing fewer migraine days per month across placebo and Atogepant tablet doses of 10 mg, 30 mg, and 60 mg once daily (QD). The horizontal axis shows ranges of reduced migraine days, and the vertical axis shows the percentage of patients in each category.*

FDA Label Image

Diagramdescription Automatically Generated (Qulipta 04)

A line graph comparing the change from baseline in monthly migraine days with placebo and Qulipta (Atogepant) tablets at 10 mg, 30 mg, and 60 mg dosages over 12 weeks. The x-axis shows time intervals (Baseline, Weeks 1-4, Weeks 5-8, Weeks 9-12), and the y-axis represents change in migraine days. Qulipta doses show greater reductions compared to placebo, with error bars indicating standard error.*

FDA Label Image

Chart, Bar Chartdescription Automatically Generated (Qulipta 05)

Bar graph showing the percentage of patients experiencing different ranges of fewer migraine days per month with Qulipta (Atogepant) tablets at 10 mg, 30 mg, and 60 mg doses compared to placebo. The x-axis categorizes ranges of migraine day reduction, and the y-axis shows the percentage of patients for each category.*

FDA Label Image

Principal Display Panelndc 0074-7095-30qulipta™(atogepant) Tablets10 mgrx Onlycontains 30 Tablets (Qulipta 06)

Label for Qulipta 10 mg tablets, an oral human prescription drug containing atogepant. The label states the package contains 30 tablets, and it is labeled by AbbVie Inc. The packaging includes drug storage instructions, safety warnings, manufacturing information from Forest Laboratories Ireland Ltd., and legal trademark details.*

FDA Label Image

Principal Display Panelndc 0074-7096-30qulipta™(atogepant) Tabletsrx Onlycontains 30 Tablets30 mg (Qulipta 07)

Qulipta 30 mg (atogepant) tablets package label by AbbVie Inc. The label shows NDC 0074-7096-30 and contains 30 tablets. Additional details include storage instructions, manufacturer information for Forest Laboratories Ireland Ltd., and trademark attribution to Allergan Pharmaceuticals International Limited. The label also displays a barcode and product tracking data.*

FDA Label Image

Principal Display Panelndc 0074-7094-30qulipta™(atogepant) Tabletsrx Onlycontains 30 Tablets60 mg (Qulipta 08)

Packaging label for Qulipta 30 mg tablets containing atogepant, an oral prescription drug by AbbVie Inc. The label indicates a 4-tablet professional sample, not for sale, with the NDC 0074-7096-04. It features blue and dark gray color blocks, with text including dosage strength and instructions to visit QULIPTA.com for more information.*

FDA Label Image

Qulipta 09

Qulipta 60 mg (atogepant) tablets oral prescription drug label by AbbVie Inc. The package contains 30 tablets. The label includes storage instructions, manufacturer information (Forest Laboratories Ireland Ltd., Dublin, Ireland), and regulatory details. The design features the product name in large font with dosage strength prominently displayed on a dark gray and orange background.*

FDA Label Image

Qulipta 0a

Packaging label for Qulipta (atogepant) tablets, 60 mg strength. The label shows a carton design with Qulipta branding and dosage information, indicating a package containing 4 tablets. Labeler AbbVie Inc. is noted, along with usage instructions such as 'Rx Only' and 'Professional Sample - Not For Sale.' The label emphasizes the 60 mg tablet strength and includes the NDC 0074-7094.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.